These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
512 related articles for article (PubMed ID: 15389286)
1. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Okada N; Iiyama S; Okada Y; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A Cancer Gene Ther; 2005 Jan; 12(1):72-83. PubMed ID: 15389286 [TBL] [Abstract][Full Text] [Related]
2. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Okada N; Mori N; Koretomo R; Okada Y; Nakayama T; Yoshie O; Mizuguchi H; Hayakawa T; Nakagawa S; Mayumi T; Fujita T; Yamamoto A Gene Ther; 2005 Jan; 12(2):129-39. PubMed ID: 15483669 [TBL] [Abstract][Full Text] [Related]
3. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
4. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Okada N; Masunaga Y; Okada Y; Mizuguchi H; Iiyama S; Mori N; Sasaki A; Nakagawa S; Mayumi T; Hayakawa T; Fujita T; Yamamoto A Gene Ther; 2003 Oct; 10(22):1891-902. PubMed ID: 14502218 [TBL] [Abstract][Full Text] [Related]
5. Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells. Wan Y; Emtage P; Zhu Q; Foley R; Pilon A; Roberts B; Gauldie J Cell Immunol; 1999 Dec; 198(2):131-8. PubMed ID: 10648127 [TBL] [Abstract][Full Text] [Related]
7. Generation of human dendritic cells that simultaneously secrete IL-12 and have migratory capacity by adenoviral gene transfer of hCD40L in combination with IFN-gamma. Knippertz I; Hesse A; Schunder T; Kämpgen E; Brenner MK; Schuler G; Steinkasserer A; Nettelbeck DM J Immunother; 2009 Jun; 32(5):524-38. PubMed ID: 19609245 [TBL] [Abstract][Full Text] [Related]
8. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100. Xia DJ; Zhang WP; Zheng S; Wang J; Pan JP; Wang Q; Zhang LH; Hamada H; Cao X Gene Ther; 2002 May; 9(9):592-601. PubMed ID: 11973635 [TBL] [Abstract][Full Text] [Related]
9. The induction of tumor-specific CD4+ T cells via major histocompatibility complex class II is required to gain optimal anti-tumor immunity against B16 melanoma cell line in tumor immunotherapy using dendritic cells. Fujisawa Y; Nabekura T; Nakao T; Nakamura Y; Takahashi T; Kawachi Y; Otsuka F; Onodera M Exp Dermatol; 2009 Apr; 18(4):396-403. PubMed ID: 19054057 [TBL] [Abstract][Full Text] [Related]
10. Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Strome SE; Voss S; Wilcox R; Wakefield TL; Tamada K; Flies D; Chapoval A; Lu J; Kasperbauer JL; Padley D; Vile R; Gastineau D; Wettstein P; Chen L Cancer Res; 2002 Mar; 62(6):1884-9. PubMed ID: 11912169 [TBL] [Abstract][Full Text] [Related]
11. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. Ribas A; Butterfield LH; Amarnani SN; Dissette VB; Kim D; Meng WS; Miranda GA; Wang HJ; McBride WH; Glaspy JA; Economou JS Cancer Res; 2001 Dec; 61(24):8787-93. PubMed ID: 11751400 [TBL] [Abstract][Full Text] [Related]